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A Ab bs st tr ra ac ct t
The idiopathic epilepsies are genetically heterogeneous with more than 50 clinical classifications.
They are characterized by episodic seizures arising from erratic neuronal discharge in susceptible
individuals. The most common predisposing genetic cause is the recently discovered chromo-
some 15q13.3 microdeletion. Other disorders previously attributed to the same lesion include
autism, intellectual disability and schizophrenia. This phenotypic spectrum is most easily imagined
as a contiguous gene syndrome with idiopathic generalized epilepsy as the most common clinical
manifestation. Expressivity of the microdeletion in carriers is too variable for antenatal prediction
of phenotype to be possible; however, when it is detected in living affected cases, it can be taken
as the major predisposing cause for the observed phenotype. The discovery of this small 15q13.3
lesion barely scratches the surface that conceals what we ultimately need to know about the
molecular genetic mechanisms behind the common epilepsies with complex genetics, but it
provides valuable insight into how to proceed toward that goal.
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G Ge en ne et ti ic c   e ep pi il le ep ps si ie es s
Helbig and colleagues [1] have recently described the most
common inherited cause of epilepsy detected so far. Such
progress has reminded us of Ryan’s eloquent 1995 review [2]
on the mapping of genes for familial idiopathic epilepsies to
chromosomes, which he likened to creating “chinks in the(ir)
armor”. The ‘armor’ he was referring to was the enormity of
the human genome, which effectively shields the underlying
molecular defects from detection. The timing of Ryan’s
article was impeccable: epilepsy gene hunters, assisted by
rapid technological developments in molecular genetics and
bioinformatics as the Human Genome Project gained
momentum, were at the threshold of uncovering the
channelopathy paradigm for the familial epilepsies showing
Mendelian inheritance. The first genes for the monogenic
idiopathic epilepsies were about to be identified [3-7].
E Ep pi il le ep ps sy y   a as s   a a   f fa am mi il ly y   o of f   c ch ha an nn ne el lo op pa at th hi ie es s
Most of the known pathogenic culprits in epileptogenesis are
mutations in genes encoding components of neuronal ion
channels [8]. The question from the beginning was whether
knowledge of the genes underlying these familial epilepsies
would provide the clues to uncover the susceptibility genes
for common, polygenic or multifactorial epilepsies, with
their complex genetics and complex genotype-environment
interactions.
Gargus [9] suggested that multiple neuronal ion channels
might be involved in seizure susceptibility through the
additive effects of genetic variants that contribute to the
channelopathy load. Even the simple ‘monogenic’ epilepsies
show a certain level of genetic complexity, as they are
genetically heterogeneous [8]. Add to this the incompletepenetrance of mutations and variable expressivity, and one
can imagine a continuum between the apparently mono-
genic and the polygenic epilepsies [8].
A few rare and polymorphic variants in ion channel genes
have been identified that result in changes to channel
properties consistent with an increased predisposition to
seizures [8,10]. To this list of susceptibility genes we could
add the calcium channel gene CACNB4 [11], given that we
have posited previously that genetic modifiers in ‘mono-
genic’ epilepsy and susceptibility alleles in the common
epilepsies are the same [12]. Kryukov and colleagues [13]
proposed that most low frequency alleles are at least mildly
deleterious, so their association with disease can be deduced
when the proportion of low-frequency alleles is significantly
greater in cases than in controls. Results of large-scale
resequencing of ion channel genes are not yet available as a
test of that hypothesis; however, manual mutation screening
of extended gene families relevant to known mechanisms of
epileptogenesis has detected little coding genetic variation in
ion channels [14].
T Th he e   m mo os st t   p pr re ev va al le en nt t   r ri is sk k   f fa ac ct to or r   f fo or r   t th he e   g ge en ne et ti ic c
e ep pi il le ep ps si ie es s   y ye et t: :   t th he e   1 15 5q q1 13 3. .3 3   m mi ic cr ro od de el le et ti io on n
Helbig and colleagues [1] have recently reported recurrent
15q13.3 microdeletions in 1% of common idiopathic
generalized epilepsy (IGE). Most of their cases were free of
the co-morbidities of intellectual disability, autism and
schizophrenia that have previously been associated with the
15q13.3 lesion. They did not detect 15q13.3 microdeletions in
a large cohort of controls. The consortium was steered in the
direction of 15q13.3 after the same lesion had been
implicated in three other major groups of disorders. The first
group is intellectual disability and seizures, sometimes with
mild dysmorphic features and growth retardation. The
detection rate for the microdeletion in this cohort was 0.3%
and it was not present in a large control cohort [15]. The
second group is autism, with or without intellectual or
learning disability and a range of other psychiatric disorders,
not with epilepsy, but sometimes with mild dysmorphic
features. The detection rate among cases was 0.4% with a
large set of negative controls [16]. The final group is schizo-
phrenia, with a detection rate of 0.2-0.3%. The micro-
deletion was found in controls, but only in one of the two
studies at a frequency of 0.02%, representing a single
individual [17,18].
The basis for the recurrent 15q13.3 deletion mutation is most
likely non-allelic homologous recombination [19] in an
unstable region of the genome flanked by two highly
homologous segmental duplication regions. The reciprocal
product, the microduplication, has been detected in both the
patient cohorts and the controls, but it has not been
implicated in any of the disorders associated with the
microdeletion. The rarity of the 15q13.3 microdeletion in
controls strongly suggests that it is under strong natural
selection and maintained at low frequency by the balance
between recurrent mutation and selection.
One of seven contiguous genes deleted in the smallest
interval common to all 15q13.3 microdeletions associated
with IGE [1] is the α7 gene of the acetylcholine receptor
(CHRNA7). Mutations in three acetylcholine receptor sub-
units (α2, α4 and β2) are causative for epilepsy [8]. Helbig
and colleagues [1] therefore postulated that CHRNA7 is the
likely culprit in the IGE cohort, just as others have suggested
it to account for epilepsy where it occurred in the
intellectually challenged cohort [15]. CHRNA7 was also an
attractive candidate for schizophrenia on the basis of
previous linkage results [17].
The IGE subsyndromes found to be associated with the
15q13.3 lesion are childhood absence epilepsy (CAE),
juvenile absence epilepsy (JAE) and juvenile myoclonic
epilepsy (JME) [1]. It is tempting to use this to support the
notion that the same genetic determinants can be causal in
different subsyndromes of the common epilepsies, and
indeed more broadly between epilepsy and other complex
brain disorders, such as autism, intellectual disability and
schizophrenia. However, this argument holds true only if the
entire spectrum of associated phenotypes can be attributed
to haploinsufficiency of only one of the missing genes, for
example CHRNA7. The microdeletion removes a copy of
seven genes [1] and may affect transcription of other
structurally unaffected genes; any of these genes alone or in
combination could be involved in the genesis of the
multifaceted phenotype arising from this lesion.
The finding of Helbig and colleagues [1] demonstrates the
potential role of structural variation in accumulating a
genetic load predisposing to IGE, in addition to single
nucleotide polymorphisms (SNPs) in ion channel or other
brain-expressed genes. High-density probe arrays are now
available for high-resolution interrogation of the entire
genome for lesions, such as the one at 15q13.3, for any
disorder with complex genetics. Furthermore, the wealth of
structural variations known throughout the entire human
genome represents a pool of potential genetic modifiers for
any number of genes that might participate in molding the
final phenotype associated with the 15q13.3 deletion.
A A   c co on nt ti ig gu uo ou us s   g ge en ne e   s sy yn nd dr ro om me e   a at t   1 15 5q q1 13 3. .3 3   o or r   a a   s si in ng gl le e- -
g ge en ne e   C CH HR RN NA A7 7 d di is so or rd de er r? ?
As exciting as this new finding of an association between the
15q13.3 microdeletion and IGE is for the genetics of epilepsy,
it raises unanswered questions. The contiguous genes always
missing from the chromosome 15 homolog with the deletion
are those encoding the Rho GTPase activating protein 11B
(ARHGAP11B), myotubularin-related protein 10 (MTMR10),
myotubularin-related protein 15 (MTMR15), transient receptor
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(KLF13), OTU domain-containing deubiquitinating enzyme
(OTUD7A) and CHRNA7 [1]. Given the range of phenotypes
associated with this microdeletion from cohorts originating
from different medical disciplines, it is highly possible that
more than just the one gene, CHRNA7, is pathogenically
involved. But of the six other genes, only OTUD7A is known
to be expressed in the brain, and it encodes a de-
ubiquitinating enzyme. Such enzymes are generally involved
in multiple biochemical pathways.
A variety of potential mechanisms could be invoked to
explain the observed range of disease phenotypes. Patho-
genicity of the deletion could be explained by: (i) a position
effect arising from a juxtaposition of genes creating new
promoter relationships; (ii) deregulation of transcription of
nearby genes that are not structurally deleted themselves but
for which some or all regulatory elements are deleted; (iii)
haploinsufficency for any of the deleted genes; (iv) exposure
of deleterious recessive alleles at any of the seven genes
present on the normal chromosome 15 homolog; or (v) a
combination of mechanisms involving any of the above.
Two of the deleted genes have been knocked out in mice. The
CHRNA7 mouse knockout has neocortical electroencephalo-
gram abnormalities suggestive of predisposition to epilepsy
[20] and mild impairment of working/episodic-like memory,
which fits within the human schizophrenia spectrum [21].
KLF13 is a transcription factor, and mouse knockouts show
that it is necessary for normal control of erythropoiesis [22],
while other members of this Krüppel-like factor family are
known to have roles in development. These animal models
fail to resolve the question of whether defective CHRNA7
alone could account for the entire range of phenotypes asso-
ciated with the human 15q13.3 microdeletion. Ultimately,
CHRNA7 will need to be resequenced in the cohorts in which
the 15q13.3 microdeletion was detected to determine
whether DNA sequence mutations in CHRNA7 alone can
account for the same range of phenotypes.
A synthesis of results from all cohorts in which the 15q13.3
lesion has been detected - pending the outcome of large scale
CHRNA7 resequencing, which might challenge the following
interpretation - strongly suggests a new and as-yet unnamed
contiguous gene syndrome with highly variable expression.
The cohort in which expression is primarily restricted to
epilepsy alone probably represents the phenotype close to
the milder end of the disease spectrum associated with this
microdeletion. Non-penetrance, in which the lesion has been
found in asymptomatic carriers in family studies [1],
represents the extreme end of the spectrum. Just as the
highly variable expressivity incorporated into the clinical
concept of ‘genetic (generalized) epilepsy with febrile
seizures plus’ (GEFS+) [23] was validated by the discovery of
a familial mutation responsible for the phenotypic variations
[7], the microchromosomal deletion is the genetic diagnostic
marker for, and thus validates, the 15q13.3-related clinical
syndrome with its multiple clinical manifestations. The
concept of the spectrum solves the dilemma of how to
clinically classify individuals into their respective disease
cohorts in the presence of complex overlapping morbidities.
We do not have to do this classification if we regard the
multiple clinical manifestations as one contiguous gene
syndrome. The corollary to this concept of a single multi-
genic syndrome is that phenotype cannot be predicted from
antenatal detection of the lesion, making its utility as a
genetic test uncertain other than as a postnatal marker to
explain symptoms.
P Pe er rs sp pe ec ct ti iv ve es s   a an nd d   p pr re ed di ic ct ti io on ns s
So where are we at for the epilepsies with complex genetics?
Mullen and colleagues [24] have reviewed the principles of
genome-wide association studies (GWASs) with great clarity
and optimism in the context of the epilepsies. An alternative
view is that the frequency of most susceptibility SNPs in
epilepsy could be so rare, or individually could make such
small contributions toward raising the seizure threshold,
that GWASs are not sensitive enough to detect them. We
have previously expressed this view as the Realistic Model
[12] and as later renamed the Polygenic Heterogeneity
Model [10]. This model remains lacking in detail pending
the accumulation of additional real data and was formulated
in the limited context of coding SNPs within ion channel
genes. However, evidence is now mounting from other brain
disorders with complex genetics (schizophrenia and autism)
that large numbers of rare or novel structural chromosomal
variants may be responsible for the major fraction of disease
risk [17,25,26]. The polygenic heterogeneity model may be
correct in principle, but it may now require the inclusion of
copy number variants (CNVs) as its dominant feature, with
SNP variation relegated to a secondary role. The greater
potential of multiple, rare structural variants as effectors in
disorders with complex genetics is highlighted by the fact
that the differences between all of us at the CNV level is
about double that at the SNP level [27].
IGE comprises only about 20-30% of all epilepsy [28], and
only about 1% of IGE has the most common predisposing
lesion at 15q13.3 [1]. There are now far more sophisticated
molecular technologies to direct at Ryan’s armor analogy
[2], now in the context of the epilepsies with complex
genetics, but our understanding of their molecular genetic
basis remains very limited despite the significant advance
reported by Helbig and colleagues [1]. Piercing the armor to
dissect out the genetic architecture underlying the common
epilepsies might require more than a few ‘artillery shots’
aimed at the bigger targets such as common polymorphic
variants (as in GWASs looking for associations in popu-
lations that have so far eluded the gunner’s aim [29,30]).
Instead of or in addition to this, it might require a
comprehensive peppering of affected individuals examined
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comparative genome hybridization (array CGH), in which
the causative defects in most affected individuals with
genetic epilepsies could be different structural variants
possibly involving blocks of genes, as in the 15q13.3
microdeletion). CGH hits have uncovered multiple rare
structural variants for autism and schizophrenia [17,25,26]
where GWASs had made little progress toward uncovering
common susceptibility alleles. We suggest the same CGH
approach is now the way forward for the genetic epilepsies,
with the report of Helbig and colleagues [1] representing a
tantalizing preview of what is yet to come. Some time ago for
the same 15q13.3 region Taske and colleagues [31] examined
CHRNA7 as a positional candidate for JME following an
earlier linkage study [32] and predicted the possibility of
disease-causing genomic rearrangements in this unstable
region after they were unable to find unequivocal DNA
sequence mutations in CHRNA7. The gene content of each
new structural lesion or CNV polymorphism to be associated
with epilepsy would represent an accumulation of the ‘chips
off the armor’ slowly uncovering the presently concealed
complex genetic architecture underlying the common
genetic epilepsies.
A Ab bb br re ev vi ia at ti io on ns s
ARHGAP11B, Rho GTPase activating protein 11B; CACNB4,
calcium channel β4 subunit; CAE, childhood absence
epilepsy; CGH, comparative genome hybridization; CHRNA7,
acetylcholine receptor α7 subunit; CNV, copy number
variant; GEFS+, genetic (generalized) epilepsy with febrile
seizures plus; GWAS, genome-wide association study; IGE,
idiopathic generalized epilepsy; JAE, juvenile absence
epilepsy; JME, juvenile myoclonic epilepsy; KLF13, Krüppel-
like factor 13; MTMR10, myotubularin-related protein 10;
MTMR15, myotubularin-related protein 15; OTUD7A, OTU
domain-containing deubiquitinating enzyme; SNP, single
nucleotide polymorphism; TRPM1, transient receptor
potential cation channel.
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